Granules India expects 30% growth in FY14

Harsha Chigurupati, director, Granules India, says that last year the company reported a major increase in profit due to forex gains of around Rs 8 crore. This year too, the company performed better than previous year. There has been improvement in revenues and the company expects revenues to grow at 30 percent in FY14.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead master your money Realasset
moneycontrol.com

Home » News » Earnings » Results Boardroom

Apr 26, 2013, 05.41 PM | Source: CNBC-TV18

Granules India expects 30% growth in FY14

Harsha Chigurupati, director, Granules India, says that last year the company reported a major increase in profit due to forex gains of around Rs 8 crore. This year too, the company performed better than previous year. There has been improvement in revenues and the company expects revenues to grow at 30 percent in FY14.

Like this story, share it with millions of investors on M3

Granules India expects 30% growth in FY14

Harsha Chigurupati, director, Granules India, says that last year the company reported a major increase in profit due to forex gains of around Rs 8 crore. This year too, the company performed better than previous year. There has been improvement in revenues and the company expects revenues to grow at 30 percent in FY14.

Post Your Comments

Share Cancel

Harsha Chigurupati, director, Granules India , says last year the company reported a major increase in profit due to forex gains of around Rs 8 crore. This year too, the company performed better than previous year. There has been improvement in revenues and the company expects revenues to grow at 30 percent in FY14.

Also read: Granules India consolidated Mar '13 sales at Rs 204.38 crore

Below is the edited transcript of his interview to CNBC-TV18.

Q: Your net profit is impacted by one-time gain that you had on forex last year. Shaved off that how does the performance look on the bottom-line front and also on the operating profit front?

A: Last year the major increase in profit was due to forex gains of around Rs 8 crore. If we shave off Rs 8 crore from last year then also the performance of last year was ahead compared to the year before that. So, we did relatively better compared to previous year.

Q: What accounted for that improved performance because revenues are flat about Rs 200 crore compared to Rs 188 crore year ago quarter? What boosted the performance?

A: One can easily make out from the number that revenues have grown. There has been a significant increase in our existing capacity and we have utilized ourselves even better.

We are focusing on innovation and operational efficiencies. We have taken our existing assets, worked on the operation efficiencies especially for the APIs and got more product out of it. So our revenue and profitability increased.

Q: How much Gagillapur facility expansion will add to your top line this year?

A: From pure capacity standpoint, capacity enhancement is quite novel and never done before in the world. We have a pure large scale production business model and it is very unique and due to that our infrastructure is quite unique. It gives us efficiency in the way other companies cannot achieve for large scale. We expect revenue to increase by over 30 percent from the previous year.

Q: Thirty percent in terms of revenue growth because of the added capacity?

A: Yes exactly. If revenue is 30 percent, then profitability will be significantly higher than 30 percent. Profitability is not only based on revenue growth it is again based on innovative manufacturing process which will give us efficiency and we also have a better product mix. These are mainly for finished dosages which have better margins. 

Q: You get to the high teens in terms of margins because you have been averaging around 13 percent, which has been your best performance so far?

A: EBITDA would be in high teens and significant difference because of two things, better capacity in terms of efficiency and better product mix. Also better dosage more from API granulation to more finished dosages.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Granules India expects 30% growth in FY14

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login